Press Releases

Date Title and Summary Additional Formats
Toggle Summary NewLink Genetics Corporation Announces Pricing for Initial Public Offering
NewLink Genetics Corporation Announces Pricing for Initial Public Offering AMES, Iowa, Nov. 11, 2011 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK) announced today the initial public offering of 6,200,000 shares of its common stock at a price of $7.00 per share.
View HTML
Toggle Summary NewLink Announces Board Member Appointment
NewLink Announces Board Member Appointment AMES, Iowa, Oct. 7, 2011 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation, a privately held biopharmaceutical company, today announces that Mr. Paul R. Edick was appointed as a director of NewLink Genetics Corporation. Mr.
View HTML
Toggle Summary NewLink Genetics to Present Data on Its HyperAcute(R) Prostate and Melanoma Immunotherapies at the American Society of Clinical Oncology Annual Meeting
NewLink Genetics to Present Data on Its HyperAcute(R) Prostate and Melanoma Immunotherapies at the American Society of Clinical Oncology Annual Meeting AMES, Iowa, May 31, 2011 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation today announced that data from its investigational HyperAcute® Prostate
View HTML
Toggle Summary NewLink Genetics to Present Phase 2 Data of Its HyperAcute(R) Lung Immunotherapy at AACR 102nd Annual Meeting 2011
NewLink Genetics to Present Phase 2 Data of Its HyperAcute(R) Lung Immunotherapy at AACR 102nd Annual Meeting 2011 AMES, Iowa, April 1, 2011 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation today announced that additional data from its Phase 2 clinical trial of the Company's investigational
View HTML